首页 | 本学科首页   官方微博 | 高级检索  
     


NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity‐modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer
Authors:Akila N. Viswanathan MD  MPH  Jennifer Moughan MS  Brigitte E. Miller MD  Ying Xiao PhD  Anuja Jhingran MD  Lorraine Portelance MD  Walter R. Bosch DSc  Ursula A. Matulonis MD  Neil S. Horowitz MD  Robert S. Mannel MD  Luis Souhami MD  Beth A. Erickson MD  Kathryn A. Winter MS  William Small MD Jr  David K. Gaffney MD  PhD
Affiliation:1. Department of Radiation Oncology, Brigham and Women's Hospital, Dana‐Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts;2. NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania;3. Carolinas Healthcare System NorthEast, Levine Cancer Institute, Concord, North Carolina;4. Thomas Jefferson University Hospital, Philadelphia, Pennsylvania;5. The University of Texas MD Anderson Cancer Center, Houston, Texas;6. University of Miami Miller School of Medicine, Miami, Florida;7. Washington University, St. Louis, Missouri;8. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;9. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA;10. University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma;11. McGill University, Montreal, Quebec, Canada;12. Medical College of Wisconsin, Milwaukee, Wisconsin;13. Loyola University, Chicago, Illinois;14. University of Utah Health Science Center, Salt Lake City, Utah
Abstract:
Keywords:endometrial cancer  radiation  bevacizumab  chemotherapy  intensity‐modulated radiotherapy (IMRT)
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号